Long-term follow-up for HPV vaccine study participants
Part of Infections clinical trials.
This study checks on people who got one or two doses of the HPV vaccine (Gardasil 9) during the earlier ESCUDDO study. It helps researchers see how well the vaccine protects over many years, which might lead to simpler vaccination schedules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the original ESCUDDO HPV vaccine study
- You received either one or two doses of Gardasil 9 in that study
- You can come to three study visits
- You are between 21 and 26 years old for the survey part
- You are not pregnant and have not had the HPV vaccine since the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with people who received the bivalent HPV vaccine to see how long their protection lasts and whether any breakthrough infections occur. It involves extra blood tests or follow-up visits over several years.
This study checks if one dose of the 9-valent HPV vaccine given at ages 9-11 still protects you 6 years later. It is for people who only had that single dose and no other HPV shots.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
This study tests a vaccine against HPV (a virus that can cause certain cancers) given alone or with a tetanus-diphtheria (Td) booster. It is for healthy children aged 9 to 15 to see if the vaccines are safe and produce a good immune response.
Hear when a new Human Papillomavirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.